Interactions between adrenal-regulatory and calcium-regulatory hormones in human health

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 3, 2014, Pages 193-201

  Brown, Jenifer M ^a   Vaidya, Anand ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

parathyroid hormone; renin angiotensin aldosterone system; vitamin D

Indexed keywords

ADRENAL REGULATORY HORMONE; ALDOSTERONE; ANGIOTENSIN II; CALCIUM REGULATORY HORMONE; HORMONE; PARATHYROID HORMONE; RENIN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR; MINERALOCORTICOID ANTAGONIST;

CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; HEALTH STATUS; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HUMAN; HYPERALDOSTERONISM; HYPERPARATHYROIDISM; MUSCULOSKELETAL SYSTEM; OSTEOLYSIS; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CARDIOVASCULAR DISEASE; FEMALE; MALE; METABOLISM; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIMARY HYPERPARATHYROIDISM;

ALDOSTERONE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERPARATHYROIDISM, PRIMARY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OSTEOPOROSIS; PARATHYROID HORMONE; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 84899950212     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000062     Document Type: Review

References (88)

1. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98:121-128.
2. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 2010; 105: 10A-20A.
3. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
5. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
6. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation 2003; 108:1831-1838.
7. Carbone LD, Cross JD, Raza SH, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008; 52:135-138.
8. Van Ballegooijen AJ, Reinders I, Visser M, et al. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 2013; 98:E638-E645.
9. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 2014; 63:20-31.
10. Vaidya A, Forman JP. Vitamin D and vascular disease: the current and future status of vitamin D therapy in hypertension and kidney disease. Curr Hypertens Rep 2012; 14:111-119.
11. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
12. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4:283-291.
13. Vestergaard P, Mollerup CL, Frøkjaer VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321:598-602.
14. Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 2012; 97: E75-E79.
15. Maniero C, Fassina A, Seccia TM, et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens 2012; 30:390-395.
16. Maniero C, Fassina A, Guzzardo V, et al. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 2011; 58:341-346.
17. Brown JM, Williams JS, Luther JM, et al. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension 2014; 63:273-280.
18. Atchison DK, Beierwaltes WH. The influence of extracellular and intracellular calcium on the secretion of renin. Pflugers Arch 2013; 465:59-69.
19. Fallo F, Rocco S, Pagotto U, et al. Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism. J Hypertens Suppl 1989; 7:S192-S193.
20. Kitazawa S, Fukase M, Kitazawa R, et al. Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer 1991; 67:984-989.
21. Saussine C, Judes C, Massfelder T, et al. Stimulatory action of parathyroid hormone on renin secretion in vitro: a study using isolated rat kidney, isolated rabbit glomeruli and superfused dispersed rat juxtaglomerular cells. Clin Sci (Lond) 1993; 84:11-19.
22. Grant FD, Mandel SJ, Brown EM, et al. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab 1992; 75:988-992.
23. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
24. Vaidya A, Forman JP, Hopkins PN, et al. 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst 2011; 12:311-319.
25. Vaidya A, Sun B, Larson C, et al. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. J Clin Endocrinol Metab 2012; 97:2456-2465.
26. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 1985; 78:385-390.
27. Rossi E, Sani C, Perazzoli F, et al. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995; 8:884-893.
28. Rossi GP, Ragazzo F, Seccia TM, et al. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 2012; 60:431-436.
29. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004; 287:H2023-H2026.
30. Runyan AL, Chhokar VS, Sun Y, et al. Bone loss in rats with aldosteronism. Am J Med Sci 2005; 330:1-7.
31. Salcuni AS, Palmieri S, Carnevale V, et al. Bone involvement in aldosteronism. J Bone Miner Res 2012; 27:2217-2222.
32. Ceccoli L, Ronconi V, Giovannini L, et al. Bone health and aldosterone excess. Osteoporos Int 2013; 24:2801-2807.
33. Beavan S, Horner A, Bord S, et al. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 2001; 16:1496-1504.
34. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52:519-530.
35. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70:351-357.
36. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-2218.
37. Koiwa F, Komukai D, Hirose M, et al. Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients. Clin Exp Nephrol 2012; 16:130-135.
38. Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid 'escape' in man. Kidney Int 1972; 2:279-286.
39. Rossi E, Perazzoli F, Negro A, et al. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens 1998; 11:8-13.
40. Tomaschitz A, Fahrleitner-Pammer A, Amrein K, et al. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord 2012; 12:19.
41. Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:351-365.
42. Lind L, Ridefelt P, Rastad J, et al. Relationship between abnormal regulation of cytoplasmic calcium and elevated blood pressure in patients with primary hyperparathyroidism. J Hum Hypertens 1994; 8:113-118.
43. Letizia C, Ferrari P, Cotesta D, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens 2005; 19:901-906.
44. Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism - effects of parathyroidectomy. Surgery 2000; 128:895-902.
45. Vestergaard P, Mollerup CL, Frøkjaer VG, et al. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003; 27:216-222.
46. Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50:321-328.
47. Stefenelli T, Abela C, Frank H, et al. Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. Surgery 1997; 121:157-161.
48. Hedbäck G, Odén A. Increased risk of death from primary hyperparathyroidism - an update. Eur J Clin Invest 1998; 28:271-276.
49. Nilsson IL, Yin L, Lundgren E, et al. Clinical presentation of primary hyperparathyroidism in Europe - nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002; 17 (Suppl. 2):N68-N74.
50. Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2011; 75:169-176.
51. Nainby-Luxmoore JC, Langford HG, Nelson NC, et al. A case-comparison study of hypertension and hyperparathyroidism. J Clin Endocrinol Metab 1982; 55:303-306.
52. Ringe JD. Reversible hypertension in primary hyperparathyroidism - pre and postoperative blood pressure in 75 cases. Klin Wochenschr 1984; 62:465-469.
53. Rosa J, Raska I, Wichterle D, et al. Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens Res 2011; 34:296-300.
54. Rubin MR, Maurer MS, McMahon DJ, et al. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:3326-3330.
55. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin- aldosterone system. J Renin Angiotensin Aldosterone Syst 2004; 5:102-108.
56. Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014; 8:72-82.
57. Rossi GP. Hyperparathyroidism arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res 2011; 34:286-288.
58. Jorde R, Sundsfjord J, Fitzgerald P, Bønaa KH. Serum calcium and cardiovascular risk factors and diseases: the Tromsø study. Hypertension 1999; 34:484-490.
59. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008; 156:556-563.
60. Lind L, Skarfors E, Berglund L, et al. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 1997; 50:967-973.
61. Atchison DK, Harding P, Beierwaltes WH. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calciumsensing receptor. Hypertension 2011; 58:604-610.
62. Spangler WL, Gribble DH, Lee TC. Vitamin D intoxication and the pathogenesis of vitamin D nephropathy in the dog. Am J Vet Res 1979; 40:73-83.
63. Watanabe S, Fukumoto S, Chang H, et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002; 360:692-694.
64. Mateus-Hamdan L, Beauchet O, Bouvard B, et al. High parathyroid hormone, but not low vitamin D concentrations, expose elderly inpatients to hypertension. Geriatr Gerontol Int 2013; 13:783-791.
65. Van Ballegooijen AJ, Visser M, Kestenbaum B, et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol 2013; 111:418-424.
66. Van Ballegooijen AJ, Visser M, Cotch MF, et al. Serum vitamin Dand parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab 2013; 98:2544-2552.
67. Deo R, Katz R, Shlipak MG, et al. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension 2011; 58:1021-1028.
68. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31:1591-1598.
69. Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009; 119:2765-2771.
70. Barkan A, Marilus R, Winkelsberg G, et al. Primary hyperparathyroidism: possible cause of primary hyperaldosteronism in a 60-year-old woman. J Clin Endocrinol Metab 1980; 51:144-147.
71. Brunaud L, Germain A, Zarnegar R, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery 2009; 146:1035-1041.
72. Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2:360-370.
73. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res 2012; 94: 10-19.
74. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 2001; 280:E209-E213.
75. Kovács L, Góth MI, Szabolcs I, et al. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 1998; 138:543-547.
76. Helwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology 1991; 129:1233-1242.
77. Bernini G, Moretti A, Lonzi S, et al. Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery. Metabolism 1999; 48:298-300.
78. Vaidya A, Williams JS. The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism 2012; 61:450-458.
79. Yuan W, Pan W, Kong J, et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282:29821-29830.
80. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88:327-331.
81. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010; 55:1283-1288.
82. Tomaschitz A, Pilz S, Ritz E, et al. Independent association between 1,25- dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2010; 411:1354-1360.
83. Vaidya A, Sun B, Forman JP, et al. The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians. Clin Endocrinol (Oxf) 2011; 74:783-790.
84. Shoback DM, Williams GH, Moore TJ, et al. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 1983; 72:2115-2124.
85. Redgrave J, Rabinowe S, Hollenberg NK, Williams GH. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 1985; 75:1285-1290.
86. Lee MA, Böhm M, Paul M, Ganten D. Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation 1993; 87: IV7-IV13.
87. Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system - focusing on the vascular system. Peptides 2011; 32:2141-2150.
88. Brown JM, Secinaro K, Williams JS, Vaidya A. Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study. BMC Endocr Disord 2013; 13:33.